Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease

Annals of the American Thoracic Society

Volumn 11, Issue 5, 2014, Pages 685-694

  Sharif, Roozbeh ^a,b   Parekh, Trisha M ^a   Pierson, Karen S ^c   Kuo, Yong Fang ^a,c   Sharma, Gulshan ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Graduate School of Biomedical Sciences Galveston   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Chronic obstructive pulmonary disease; Follow up visit; Hospital readmission

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STEROID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA BASE; DEPRESSION; DIABETES MELLITUS; FEMALE; FOLLOW UP; GROUPS BY AGE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH INSURANCE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OXYGEN THERAPY; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; RISK FACTOR; CLINICAL TRIAL; DISEASE COURSE; INCIDENCE; MEDICARE; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TRENDS; UNITED STATES;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MEDICARE; MIDDLE AGED; PATIENT READMISSION; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84903616299     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201310-358OC     Document Type: Article

References (48)

1. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y, Wang Y, Lin Z, Straube BM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2009; 2:407-413.
2. Krumholz HM, Normand SL, Spertus JA, Shahian DM, Bradley EH. Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) 2007;26: 75-85.
3. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Hospital Compare, 2014. Available from: http://www.medicare. gov/hospitalcompare/search.html
4. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360:1418-1428.
5. Camberg LC, Smith NE, Beaudet M, Daley J, Cagan M, Thibault G. Discharge destination and repeat hospitalizations. Med Care 1997; 35:756-767.
6. Westert GP, Lagoe RJ, Keskimäki I, Leyland A, Murphy M. An international study of hospital readmissions and related utilization in Europe and the USA. Health Policy 2002;61:269-278.
7. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM; Estudi del Factors de Risc d'Agudització de la MPOC Investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003;58:100-105.
8. Proposed rule clarifies admission policies. Hosp Case Manag 2013;21: 95-96.
9. Readmission reduction has begun and the penalties will escalate. Hosp Case Manag 2013;21:45-47.
10. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis 2013;8:551-559.
11. Centers for Disease Control and Prevention (CDC). Deaths from chronic obstructive pulmonary disease-United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008;57:1229-1232.
12. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
13. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 2010;170:560-565.
14. Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA. Factors associated with change in exacerbation frequency in COPD. Respir Res 2013; 14:79.
15. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011;183: 323-329.
16. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, Nordestgaard BG. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186:975-981.
17. Eriksen N, Vestbo J. Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Clin Respir J 2010;4:208-214.
18. Elixhauser A, Au DH, Podulka J. Statistical Brief #121: readmissions for chronic obstructive pulmonary disease, 2008. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
19. Krumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, Bernheim SM, Wang Y, Bradley EH, Han LF, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013;309:587-593.
20. Krumholz HM, Lin Z, Drye EE, Desai MM, Han LF, Rapp MT, Mattera JA, Normand SL. An administrative claims measure suitable for profiling hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2011;4:243-252.
21. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, Schuur JD, Stauffer BD, Bernheim SM, Epstein AJ, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008;1:29-37.
22. Lindenauer PK, Normand SL, Drye EE, Lin Z, Goodrich K, Desai MM, Bratzler DW, O'Donnell WJ, Metersky ML, Krumholz HM. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med 2011;6:142-150.
23. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
24. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009;10:45.
25. Kawasumi Y, Paterson MJ, Morrow RL, Miller TA, Bassett K, Wright JM, Dormuth CR. Comparative effectiveness of tiotropium and ipratropium in prevention of hospital readmission for COPD: a population-based cohort study. Clin Ther 2013;35:523-531, e1.
26. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007;132:1748-1755.
27. Pratt LA, Brody DJ. NCHS Data Brief: depression in the United States household population, 2005-2006. Hyattsville, MD: National Center for Health Statistics; 2008.
28. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patients with COPD: relationship to functional capacity. Chest 1985;87:35-38.
29. van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999;54:688-692.
30. Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of mental disorders on health status among patients with chronic obstructive pulmonary disease. Prim Care Companion J Clin Psychiatry 2010;12:e1-e8.
31. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011;52:441-449.
32. Coventry PA, Gemmell I, Todd CJ. Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort study. BMC Pulm Med 2011;11:49.
33. Carneiro R, Sousa C, Pinto A, Almeida F, Oliveira JR, Rocha N. Risk factors for readmission after hospital discharge in chronic obstructive pulmonary disease: the role of quality of life indicators. Rev Port Pneumol 2010;16:759-777.
34. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-2107.
35. Sundbom LT, Bingefors K. The influence of symptoms of anxiety and depression on medication nonadherence and its causes: a population based survey of prescription drug users in Sweden. Patient Prefer Adherence 2013;7:805-811.
36. Gross NJ. Novel antiinflammatory therapies for COPD. Chest 2012;142: 1300-1307.
37. Lahousse L, Loth DW, Joos GF, Hofman A, Leufkens HG, Brusselle GG, Stricker BH. Statins, systemic inflammation and risk of death in COPD: the Rotterdam Study. Pulm Pharmacol Ther 2013;26: 212-217.
38. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009;85:414-421.
39. Young RP, Hopkins R, Chan WC, Thornley S, Gamble GD. Effect of statin therapy on mortality in COPD: analysis of cause specific death in a national cohort study [abstract]. Am J Respir Crit Care Med 2013; 187:A6017.
40. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-460.
41. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA; Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-1947.
42. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010;303:2035-2042.
43. Stefan MS, Rothberg MB, Shieh MS, Pekow PS, Lindenauer PK. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest 2013;143:82-90.
44. Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med 2010;170:1664-1670.
45. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004;291:1358-1367.
46. Sin DD, Tu JV. Are elderly patients with obstructive airway disease being prematurelydischarged? Am J Respir CritCare Med2000;161:1513-1517.
47. Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, Prasad B, Bracken N, Didomenico R, Godwin PO, et al. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations: a systematic review. Ann Am Thorac Soc 2014;11:417-424.
48. Stein BD, Bautista A, Schumock GT, Lee TA, Charbeneau JT, Lauderdale DS, Naureckas ET, Meltzer DO, Krishnan JA. The validity of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for identifying patients hospitalized for COPD exacerbations. Chest 2012;141:87-93.